Natalizumab-Associated Primary Central Nervous System Lymphoma

Nixon, Menarvia; Menger, Richard; Kalakoti, Piyush; Thakur, Jai Deep; Dossani, Rimal H; Sharma, Kanika; Nanda, Anil; Guthikonda, Bharat

doi:10.1016/j.wneu.2017.09.131

Cited by 14 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A systematic review published in 2018 showed comparable safety profiles with clinical trials done in MS except new cases of basal cell carcinoma and B-cell lymphoma [122]. Primary central nervous system lymphoma was also reported when used in Crohn's disease, as well as cases of extrapulmonary sarcoidosis and PML [169][170][171].…”

Section: Safety Experience From Dmt Use In Other Conditionsmentioning

confidence: 91%

Safety of Newer Disease Modifying Therapies in Multiple Sclerosis

et al. 2020

View full text Add to dashboard Cite

In the past decade, the therapeutic arsenal for multiple sclerosis has expanded greatly. Newer more potent disease modifying therapies (DMTs) with varying mechanisms of actions are increasingly used early in the disease course. These newer DMTs include oral therapies (teriflunomide, dimethyl fumarate, fingolimod, siponimod, ozanimod, and cladribine) and infusion therapies (natalizumab, alemtuzumab, and ocrelizumab), and are associated with better control of disease activity and long-term outcomes in patients with MS compared to older injectable therapies (interferon beta and glatiramer acetate). However, they are associated with safety concerns and subsequent monitoring requirements. Adverse events are initially observed in phase 2 and 3 clinical trials, and further long-term data are collected in phase 3 extension studies, case series, and post-marketing reports, which highlight the need to periodically re-evaluate and adjust monitoring strategies to optimize treatment safety in an individualized approach.

show abstract

Section: Safety Experience From Dmt Use In Other Conditionsmentioning

confidence: 91%

Safety of Newer Disease Modifying Therapies in Multiple Sclerosis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…84 There is no generally increased risk for developing malignancies under natalizumab, suggesting that immune surveillance is not generally compromised, but there has been a number of CNS and GI lymphomas, which are areas in which natalizumab impairs immune surveillance. 85 In case of mild classical infections, natalizumab treatment can be continued. However, in case of moderate or severe infection, treatment should be postponed and appropriate treatment of infections should be initiated.…”

Section: Natalizumab (Tysabri ® )mentioning

confidence: 99%

Risks and risk management in modern multiple sclerosis immunotherapeutic treatment

Klotz

Havla

Schwab

et al. 2019

Ther Adv Neurol Disord

View full text Add to dashboard Cite

In recent years, there has been a paradigm shift in the treatment of multiple sclerosis (MS) owing to the approval of a number of new drugs with very distinct mechanisms of action. All approved disease-modifying drugs primarily work directly on the immune system. However, the identification of an ‘optimal choice’ for individual patients with regard to treatment efficacy, treatment adherence and side-effect profile has become increasingly complex including conceptual as well as practical considerations. Similarly, there are peculiarities and specific requirements with regard to treatment monitoring, especially in relation to immunosuppression, the development of secondary immune-related complications, as well as the existence of drug-specific on- and off-target effects. Both classical immunosuppression and selective immune interventions generate a spectrum of potential therapy-related complications. This article provides a comprehensive overview of available immunotherapeutics for MS and their risks, detailing individual mechanisms of action and side-effect profiles. Furthermore, practical recommendations for patients treated with modern MS immunotherapeutics are provided.

show abstract

“…Кроме того, описаны развитие лимфом головного мозга в результате трансформации лимфоматоидного гранулематоза, а также случаи развития лимфом у пациентов с гистологически подтвержденными (так называемыми «сторожевыми» очагами демиелинизации), появление которых предшествует возникновению лимфомы [19][20][21]. Описаны случаи сочетания РС и ПЛЦНС [22,23], а также развития лимфомы у пациентов с РС при терапии натализумабом [24].…”

Section: рис 2 мультифокальная диффузная крупноклеточная в-клеточнаunclassified

Multifocal central nervous system lymphoma misdiagnosed as acute disseminated encephalomyelitis

Bakulin

Stoyda

Askarova

et al. 2018

Z. nevrol. psikhiatr. im. S.S. Korsakova

View full text Add to dashboard Cite

Primary central nervous system lymphoma (PCNSL) is a rare aggressive extranodal non-Hodgkin lymphoma. Difficulties in diagnosing PCNSL are associated with the absence of pathognomonic clinical and neuroimaging findings of this disease. The article describes the clinical case of a female patient with autopsy-confirmed multifocal large-cell B-cell CNS lymphoma misdiagnosed as acute disseminated encephalomyelitis (ADEM). Clinical and neuroimaging characteristics of PCNSL and ADEM as well as the role of diagnostic methods in establishing the correct diagnosis are discussed.

show abstract

Natalizumab-Associated Primary Central Nervous System Lymphoma

Cited by 14 publications

References 24 publications

Safety of Newer Disease Modifying Therapies in Multiple Sclerosis

Safety of Newer Disease Modifying Therapies in Multiple Sclerosis

Risks and risk management in modern multiple sclerosis immunotherapeutic treatment

Multifocal central nervous system lymphoma misdiagnosed as acute disseminated encephalomyelitis

Contact Info

Product

Resources

About